Quantum BioPharma (FRA:0K91) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0K91 Quantum BioPharma Ltd FRA:0K91
38 GF Score
Price €3.48
! 5 Warning Signs
View Full Analysis

What is Quantum BioPharma Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:0K91
38GF Score
Quantum BioPharma Ltd FRA:0K91
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quantum BioPharma Business Description

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score

Get the complete analysis for FRA:0K91

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price